anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Sunitinib is a kinase inhibitor present in sunitinib malate capsules as the malate salt. Sunitinib malate is described chemically as N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate acid. The molecular formula is C 22H 27FN 4O 2• C 4H 6O 5 and the molecular weight is 532.6 g/mol. The chemical structure of sunitinib malate is: 

Sunitinib malate is a yellow or orange-yellow powder with a pKa of 8.95. The solubility of sunitinib malate is slightly soluble in water, practically insoluble in ethanol.

Sunitinib malate capsules are supplied as printed hard-shell capsules containing 12.5 mg, 25 mg, 37.5 mg, and 50 mg of sunitinib (equivalent to 16.7 mg, 33.4 mg, 50.1 mg, and 66.8 mg of sunitinib malate, respectively). The capsules contain the following inactive ingredients: croscarmellose sodium, magnesium stearate, mannitol, and povidone. The orange gelatin capsule shells contain red iron oxide, and titanium dioxide; the caramel gelatin capsule shells contain black iron oxide, red iron oxide, titanium dioxide, and yellow iron oxide; and the yellow gelatin capsule shells contain titanium dioxide, and yellow iron oxide. The white printing ink contains potassium hydroxide, propylene glycol, shellac, and titanium dioxide and the black printing ink contains black iron oxide, potassium hydroxide, propylene glycol, and shellac.
To prospectively collect and evaluate pre-operative, intra-operative, and post-operative variables for all patients undergoing surgical microwave ablation. All patients who have a surgical microwave ablation with the Neuwave system will be added to the database after their treatment and procedures have been completed. All data points will be collected from the electronic medical records (EMR) (office visit notes, operative notes, follow-up visits, CT scans, etc.). The collected data points will be utilized to study outcomes such as local/regional reoccurrences and distant occurrences related to hepatic tumor(s), whether there was complete destruction, residual disease/incomplete destruction, or recurrence at the ablation site. Overall-complications, length of stay, readmission rates, and any additional outcomes data that is relevant to MWA and improving surgical outcomes will also be collected.

There are various Microwave Ablation (MWA) systems available that are utilized at the study locations to treat hepatic tumors. For this study, the focus is on subjects treated with the Certus 140TM system from NeuWave Medical®. Certus 140TM microwave generator possesses a 2.45 gigahertz (GHz) operating frequency and can power up to 140 watts. It can deliver microwave energy through three distinct channels simultaneously through a single system and uses three distinct antenna types (LK, SR, PR). It also contains a CO2-based cooling system that helps limit the temperature of the handle and cable. It is compatible with a variety of probes (LK, SR and PR antenna) and offers two modes, Ablation mode and Surgical mode. The Ablation mode is used for ablating a substantial target for several minutes until the object of the ablation is necrotic. Surgical Mode is used to ablate or coagulate a target for shorter periods of time while frequently moving the probe in a technique known as "planar coagulation."

Current data and manufacturer guidelines for recommended ablation energy outputs for microwave ablation systems are obtained via ex vivo and animal models with tissues that exhibit different properties of energy transference than in vivo human tissues, particularly, human hepatic solid tumors. The objective is to prospectively assess the thermodynamics of microwave ablation energy in this context, specifically through the creation of power/time curves to predict future ablation volumes through single applications of MWA energy per lesion.
PD-1 antagonists are disclosed that can be used to reduce the expression or activity of PD-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced using these PD-1 antagonists in conjunction with an antigen from the infectious agent or tumor. Thus, subjects with infections, such as persistent infections can be treated using PD-1 antagonists. In addition, subjects with tumors can be treated using the PD-1 antagonists. In several examples, subjects can be treated by transplanting a therapeutically effective amount of activated T cells that recognize an antigen of interest and by administering a therapeutically effective amount of a PD-1 antagonist. Methods are also disclosed for determining the efficacy of a PD-1 antagonist in a subject administered the PD-1 antagonist. In some embodiments, these methods include measuring proliferation of memory B cells in a sample from a subject administered the PD-1 antagonist.
PURPOSE: A composition for preventing or treating obesity containing germinated brown rice extract is provided to be used in health food without toxicity and side effects. CONSTITUTION: A composition for preventing or treating obesity contains germinated brown rice extract as an active ingredient. The extract is methanol extract. The composition additionally contains pharmaceutically acceptable carrier. A composition for suppressing adipose accumulation contains germinated brown rice extract as an active ingredient. A composition for suppressing adipocyte precursor cell contains the germinated brown rice extract as an active ingredient. The composition is used in the form of tablet, granule, capsule, liquid formulation or syrup.
ADR (adenoma detection rate) is generally accepted quality indicator. For possible gaming with ADR other indicators are needed. MAP (mean adenoma per colonoscopy) reflects the quality of examination of entire colon and is considered to be the most objective quality indicator. The aim of our study is to compare MAP with ADR and PDR (polyp detection rate) of all colonoscopists in our department.

We want to retrospectively assess the quality indicators of all colonoscopies from January 2013 to December 2017. We want to calculate ADR, PDR and MAP of all our endoscopists for all colonoscopies in patients over 50 years of age excluding therapeutic, IBD, management of complications and sigmoidoscopies (screening, surveillance, diagnostic) and separately only for screening colonoscopies. Correlations between MAP/ADR and MAP/PDR will be performed using Pearson´s correlation coefficient.
BACKGROUND AND OBJECTIVE: Severe acute respiratory syndrome coronavirus 2 attacks the neural system directly and indirectly via various systems, such as the nasal cavity, olfactory system, and facial nerves. Considering the high energy requirement, lack of antioxidant defenses, and high amounts of metal ions in the brain, oxidative damage is very harmful to the brain. Various neuropathic pain conditions, neurological disorders, and neuropsychiatric complications were reported in Coronavirus disease 2019, prolonged Coronavirus disease 2019, and after Coronavirus disease 2019 immunization. This manuscript offers a distinctive outlook on the interconnectedness between neurology and neuropsychiatry through its meticulous analysis of complications.
DISCUSSION: After recovering from Coronavirus disease 2019, approximately half of the patients reported developing Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Long Coronavirus disease 2019 imaging reports illustrated the hypometabolism in various parts of the brain, such as olfactory bulbs, limbic/paralimbic domains, the brainstem, and the cerebellum. Ninety imaging and neuropathological studies of Coronavirus disease 2019 have shown evidence of white matter, brainstem, frontotemporal, and oculofrontal lesions. Emotional functions, such as pleasant, long/short-term memory, movement, cognition and cognition in decision-making are controlled by these regions. The neuroinflammation and the mechanisms of defense are well presented in the discussion. The role of microglia activation, Inducible NO synthase, Cyclooxygenases ½, Reactive oxygen species, neurotoxic toxins and pro-inflammatory cytokines, such as Interleukin-1 beta, Interleukin-6 and Tumor Necrosis Factor-alpha are highlighted in neuronal dysfunction and death. Nuclear factor kappa-light-chain-enhancer of activated B cells, Mitogen-activated protein kinase, Activator Protein 1, and Interferon regulatory factors are the main pathways involved in microglia activation in Coronavirus disease 2019 neuroinflammation.
CONCLUSION: The neurological aspect of Coronavirus disease 2019 should be highlighted. Neurological, psychological, and behavioral aspects of Coronavirus disease 2019, prolonged Coronavirus disease 2019, and Coronavirus disease 2019 vaccines can be the upcoming issues. We need a global awareness where this aspect of the disease should be more considered in health research.
Patients randomized to the cases group will receive their nutrition over a period of 12-16 hours, with minimum 8 hours of fasting and maximum 12 hours of fasting. All patients will receive 100% of their daily nutrition.
The present disclosure relates to the field of biotechnology, and provides a macrophage specific chimeric antigen receptor, a controllable polarized monocyte/macrophage expressing the receptor, a preparation method therefor and an application thereof. The present disclosure provides a chimeric antigen receptor, comprising an extracellular antigen-binding domain, a transmembrane domain, and an intracellular activation domain connected in sequence. The extracellular antigen-binding domain comprises a signal peptide and/or scFv, and can specifically recognize a cell membrane surface protein EGFRvIII specifically expressed by GBM. The transmembrane domain comprises CD8α, and is linked to the extracellular antigen-binding domain and the intracellular activation domain. The intracellular activation domain comprises TIR, CD3ZETA, or GM-CSFRα/βCD3, and promotes the polarization of macrophage into M1 type. The chimeric antigen receptor of the present disclosure is introduced into macrophage, so that the macrophage has a targeted killing effect on GBM, and the M1 polarization state of the macrophage is effectively promoted and maintained.
Eight, 90 minute group sessions. Three of the sessions focused on health education (e.g., medication adherence, nutrition, exercise) and five focused on HIV prevention skills (e.g., condom skills, communication, social support). Each individual completed assessments at immediate post intervention, 3-, 6-, and 12- months. At the end of the 12-month assessment, the participants in this arm were given the option to receive the 3 trauma-focused sessions from the Trauma + HIV group arm.
ABSTRACT          A composition is prepared for treatment of a wide variety of medical disorders.  The preparation is also effective in promoting hair growth  and preventing hair  loss.    One embodiment of the composition is comprised of fenugreek, whey and alcohol.  Use of rubbing alcohol in the preparation provides a salve for treatment of a wide variety of skin disorders including disorders of the scalp.  Use of an alcoholic liquor, for  example, brandy,  provides  a  preparation  suitable  for treatment for throat irritation and cankers of the lining of the mouth cavity.  In another embodiment, fenugreek may be mixed with talcum powder to prepare  a composition suitable  for treatment  of  skin  disorders  including  venereal  disease, athlete's foot and diaper rash.
The application relates to the field of antibodies, in particular to an enterovirus A71 monoclonal antibody and application thereof. The A71 monoclonal antibody comprises a heavy chain variable region containing HCDR1, HCDR2 and HCDR3 sequences and a light chain variable region containing LCDR1, LCDR2 and LCDR3 sequences; wherein, the sequence of HCDR1 comprises the sequence shown in SEQ ID No. 1; the sequence of HCDR2 comprises the sequence shown in SEQ ID No. 2; the sequence of HCDR3 comprises the sequence shown in SEQ ID No. 3; the sequence of LCDR1 comprises a sequence shown as SEQ ID No. 4; the sequence of LCDR2 comprises the sequence shown in SEQ ID No. 5; the sequence of LCDR3 includes the sequence shown in SEQ ID No. 6. Through screening and detection, a monoclonal antibody capable of specifically binding to A71 is obtained: 1G10.1G10 is not only a powerful and effective detection tool, but also a reliable candidate for diagnostic reagents and therapeutic humanized monoclonal antibodies, detection and assay reagents for A71 vaccine screening and qualitative and quantitative determination of vaccine antigens, and antibody reference for A71 vaccine activity evaluation.
INTRODUCTION: In women of childbearing age with epilepsy, 30% experience the comorbidity of polycystic ovary syndrome (PCOS), which is marked by a higher prevalence of hyperandrogenism. Our recent clinical observations indicate the potential contribution of hyperandrogenism-induced PCOS to epilepsy susceptibility, and this study aimed to unravel the underlying factors that increase the susceptibility of females to epilepsy.
METHODS: A letrozole-induced PCOS rat model was employed to simulate endogenous hyperandrogenism. The threshold of seizure was assessed through seizure kindling rates using pentetrazol and electroencephalogram recordings. Additionally, the role of androgens in epilepsy was verified through interventions using Diane-35.
RESULTS: This study revealed that letrozole-induced elevated testosterone levels and PCOS-related changes in female rats. PCOS rats, through pentetrazol-kindling, exhibited a reduced seizure threshold compared with controls. Elevated testosterone levels were observed in both the hippocampal and frontal brain tissues, accompanied by changes in circulation. Two weeks of Diane-35 intervention showed a tendency to alleviate these changes, modifying testosterone levels in both the plasma and brain tissue. Western blotting and immunohistochemistry revealed increased expression of GABA-A receptor in the hippocampus and decreased AMPA receptor expression in the frontal cortex, correlating with antiepileptic status in PCOS rats.
CONCLUSION: This study delves into the impact of elevated androgen levels on seizure threshold, providing crucial insights into the underpinnings of the comorbidity between PCOS and epilepsy. These findings significantly contribute to the evolving field of epilepsy research, emphasizing the imperative consideration of hormonal influences for the development of targeted therapeutic interventions in individuals with epilepsy and PCOS.
Plastic and reconstructive surgeons consistently create large, raw surfaces as part of their operative procedures. Thus, plastic \& reconstructive surgery patients are among those at highest risk for anticoagulant-associated bleeding adverse drug events (ADEs). Our preliminary data has shown that a fixed, or "one size fits all" dose of enoxaparin, an anticoagulant, can allow a high proportion of patients to have appropriately thinned blood, measured by anti-Factor Xa (aFXa) levels. Patients with adequate aFXa levels are known to have significantly decreased venous thromboembolism risk (VTE), which is desirable. However, 30% of patients who receive fixed dose enoxaparin have blood that is too thin. Patients who are over-anticoagulated are significantly more likely to have ADEs including bleeding requiring return to the operating room, need for blood transfusion, or death. The optimal way to dose enoxaparin to minimize ADEs remains unknown. This study seeks to optimize both the safety and effectiveness of post-operative enoxaparin by comparing aFXa levels, bleeding events, and VTE events among plastic \& reconstructive surgery patients randomized to receive two different enoxaparin dose regimens.
Background: The objective outcomes of masseteric nerve transfer in the setting of parotid malignancy are unclear. Objective: To measure objective facial reanimation outcomes of masseteric nerve transfer in patients with parotid malignancy who underwent parotidectomy with facial nerve resection. Materials and Methods: Retrospective review of patients who underwent masseteric nerve transfer for facial paralysis secondary to parotid malignancy was carried out at a tertiary referral hospital from August 2017 to November 2021. Objective facial reanimation outcomes were analyzed using Emotrics. Minimal follow-up of 6 months was required for inclusion. Results: Eight patients (five males) with a median age of 75.5 years (range 53-91) met inclusion criteria. Fifty percent had metastatic squamous cell carcinoma, and 50% had primary parotid malignancy. Five patients underwent concomitant cancer resection with facial nerve reconstruction. Seven patients received postoperative adjuvant radiotherapy. After reinnervation, patients had improved oral commissure excursion (from 1.51 mm ±1.27 to 3.77 mm ±1.81; p < 0.01) and facial symmetry during smile. Conclusion: In this study, masseteric nerve transfer enhanced oral commissure excursion and facial symmetry during smile in patients with parotid malignancy and facial nerve resection.
Improving dietary intake among low-income youth is critical to reducing obesity, and schools are arguably the most important system in which to intervene. In 2010, Congress passed the Healthy, Hunger-Free Kids Act to better align school meal standards with the Dietary Guidelines, making school meals a nutritious option for students. Increasing participation in the school meal program, therefore, especially among low-income youth, has the potential to improve dietary intake among students and ultimately reduce childhood obesity.

Over three school years, the University of California (Berkeley's School of Public Health and the Division of Agriculture and Natural Resources' Nutrition Policy Institute) will evaluate an innovative, student-centered school-lunch intervention to increase school lunch participation and improve dietary intake among low-income middle and high school students. The project will be conducted in the San Francisco Unified School District (SFUSD), a large and diverse urban district serving over 32,000 students (70% of total) eligible for free or reduced-price meals. The intervention, developed in partnership with the global design firm IDEO, aims to promote healthier habits by leveraging principals of behavior economics. The intervention involves the following three components: 1) a smartphone application (SmartMeal) that allows students to pre-order school lunches, receive nutrition information about school lunch options, and provide feedback about meals to food service staff, 2) distributed points of sale for school meals, achieved through the addition of mobile food carts and vending machines, and 3) a staff wellness curriculum that encourages staff to promote school meals and model healthful eating behaviors to students.
Concise Summary of Project: The proposed study is a prospective, unblinded dose-ranging trial to examine in obese youth 1) the effect of correcting Vitamin D (Vit D) deficiency on insulin resistance, 2) the effect of correcting Vit D deficiency on weight gain, and 3) the amount of Vit D3 required to achieve Vit D sufficiency in obese adolescents. Subjects will be recruited from obese children and adolescents aged 6 to 17 years presenting to the COACH clinic, a referral clinic for obese children at Children's Medical Center of Dallas. Approximately 1300 new patients are seen in the COACH clinic each year. Ethnicity will be self-assigned as African-American, Caucasian, Hispanic, or Other. The ethnic makeup of the COACH clinic over the last 20 months was as follows: African-American 25%, Caucasian 19.5%, Hispanic 52%, and Other 3.5%.

As per standard practice in the COACH clinic, a height (cm), weight (kg), and blood pressure will be obtained, and body mass index (kg/m2) calculated for each patient. Fasting total cholesterol, LDL, HDL, triglyceride, 25-OHD, Hemoglobin A1c (A1c), and fasting insulin will be obtained, and an Oral Glucose Tolerance Test (OGTT) performed. The baseline estimate of insulin sensitivity is calculated from the fasting insulin and glucose values, and reported as the HOMA-IR. After Informed Consent has been obtained, participants will be randomized to either the Control group (5000 IU/wk), the Low-normal 25-OHD group (target 25-OHD 30-50 ng/mL), or the High-normal 25-OHD group (target 25-OHD 60-80 ng/mL). A 25-OHD \< 25 ng/mL will be confirmed. These groups will be matched for age (6-12 years versus 13-17 years) and ethnicity (Caucasian versus African-American verus Hispanic). Approximately 60 patients will be recruited for each group. Subject participation will continue until Vit D sufficiency has been documented for 4 consecutive months, at which point the fasting insulin and glucose values will be repeated for calculation of HOMA-IR and assessment of insulin sensitivity, and amount of weight gain will be measured.
FIELD: pharmacy. SUBSTANCE: invention relates to the powder-like preparation used for administration of medicinal useful polypeptides and containing medicinal useful polypeptide in combination with melecitose as diluting agent. Invention relates to chemical-pharmaceutical industry, in part, powder-like preparation containing medicinal useful polypeptides. Powder-like preparation containing polypeptide in combination with melecitose as diluting agent is administrated by inhalation route. Invention relates to also the method of production of the powder-like preparation. Invention provides the possibility of use of good diluting agent as compared with other diluting agents based on nonreducing sugars for making polypeptide powder-like preparations since in inhalation it shows suddenly high inhalated powder fraction. EFFECT: enhanced effectiveness of preparations. 52 cl, 2 tbl, 3 ex
Adjuvant-free recombinant influenza candidate vaccine based on Nucleoprotein in the influenza virus. One single administration intramuscularly of 480µg dose on Day1.
Sarcoma is a rare form of cancer which originates from the soft tissues and bones of the body. There are more than 50 different types of sarcoma. The primary treatment approach for most types of advanced sarcoma involves chemotherapy, but newer treatment approaches are needed because chemotherapy is not curative, sometimes does not work well, and often has significant side effects.

The purpose of this study is to evaluate a new treatment for certain types of sarcoma. The new treatment involves two oral targeted drugs used in combination: selinexor and ixazomib. Selinexor inhibits the transport of certain proteins between the nucleus and the cytoplasm of the cell. Ixazomib is part of a class of drugs called proteasome inhibitors. Currently, neither of these drugs is approved for the treatment of sarcoma. The researchers believe this combination treatment may work effectively for certain types of sarcoma based on encouraging laboratory research results. The types of sarcoma in which the treatment will be tested are: dedifferentiated liposarcoma, alveolar soft part sarcoma, malignant peripheral nerve sheath tumor, and Ewing sarcoma. The purpose of this study is to define doses of selinexor and ixazomib that are safe and tolerable for patients.
A system for self-fulfillment of an alimentary instruction set based on vibrant constitutional guidance is disclosed. The system includes at least a server. The system includes a diagnostic engine, operating on the at least a server configured to generate a diagnostic output for a user. The system includes an alimentary instruction set generator module configured to generate at least an alimentary instruction set as a function of the diagnostic output. The alimentary set generator is configured to update the at least an alimentary instruction set as a function of an alimentary self-fulfillment action. The system includes a fulfillment module which receives, from a user device at least a user entry containing the alimentary self-fulfillment action. The user entry comprises a digital reproduction from a user device. A method for self-fulfillment of an alimentary instruction set based on vibrant constitutional guidance is disclosed.